

# CMV (CYTOMEGALOVIRUS)

## QUANTITY LIMIT REQUEST

### PRESCRIBER FAX FORM

**ONLY the prescriber may complete and fax this form. This form is for prospective, concurrent, and retrospective reviews.**

**Incomplete forms will be returned for additional information.** The following documentation is required for prior authorization consideration. For formulary information and to download additional forms, please visit

<https://www.bcbstx.com/provider/medicaid/pharmacy/star-kids-prior-auth>

#### PATIENT AND INSURANCE INFORMATION

Today's Date: \_\_\_\_\_

Patient Name (First):	Last:	M:	DOB (mm/dd/yy):
Patient Address:		City, State, Zip:	Patient Telephone:
BCBSTX ID Number:		Group Number:	

#### PRESCRIBER/CLINIC INFORMATION

Prescriber Name:	Prescriber NPI#:	Specialty:	Contact Name:
Clinic Name:		Clinic Address:	
City, State, Zip:		Phone #:	Secure Fax #:

#### PLEASE ATTACH ANY ADDITIONAL INFORMATION THAT SHOULD BE CONSIDERED WITH THIS REQUEST

Patient's Diagnosis- ICD code plus description: _____	
Medication Requested: _____	Strength: _____
Dosing Schedule: _____	Quantity per Month: _____
<b>For all requests:</b>	
1. Is the patient currently treated with the requested dose of the requested medication? ..... <input type="checkbox"/> Yes <input type="checkbox"/> No <b>If yes</b> , when was treatment with the requested dose started? _____	
2. Has information been provided in support of therapy with a higher dose and/or a longer duration for the requested indication? ..... <input type="checkbox"/> Yes <input type="checkbox"/> No <b>If yes</b> , please explain: _____	
<b>For Prevyomis Requests:</b>	
3. Has the patient had an additional allogeneic hematopoietic stem cell transplant (HSCT) and requires initiation of Prevyomis? ..... <input type="checkbox"/> Yes <input type="checkbox"/> No	
<b>For Livtency Requests:</b>	
4. Does the patient have a post-transplant CMV infection/disease that is refractory to treatment (with or without genotypic resistance) with ganciclovir, valganciclovir, cidofovir, or foscarnet? ..... <input type="checkbox"/> Yes <input type="checkbox"/> No	
5. Will the patient be using the requested agent in combination with ganciclovir and/or valganciclovir for the requested indication? ..... <input type="checkbox"/> Yes <input type="checkbox"/> No	
6. Please list all other medications the patient will take <b>in combination</b> with the requested medication for the treatment of this diagnosis. _____	
7. Please list all reasons for selecting the requested <b>agent, strength, dosing schedule, and quantity over alternatives</b> (e.g., contraindications, allergies, history of adverse drug reactions to alternatives, lower dose has been tried, information supporting dose over FDA max). _____	
8. Please list all agents the patient has <b>previously tried and failed for treatment of this diagnosis</b> (Please specify if the patient has tried brand-name products, generic products, or over-the-counter products. Please specify start and end dates of drugs tried). _____ Date(s): _____ Date(s): _____ _____ Date(s): _____ Date(s): _____	

**Prescriber or Authorized Signature:** \_\_\_\_\_ **Date:** \_\_\_\_\_

*Prior Authorization of Benefits is not the practice of medicine or the substitute for the independent medical judgment of a treating physician. Only a treating physician can determine what medications are appropriate for a patient. Please refer to the applicable plan for the detailed information regarding benefits, conditions, limitations, and exclusions. The submitting provider certifies that the information provided is true, accurate, and complete and the requested services are medically indicated and necessary to the health of the patient.*

Note: Payment is subject to member eligibility Authorization does not guarantee payment.

#### Please fax or mail this form to:

Prime Therapeutics LLC, Clinical Review Department  
2900 Ames Crossing Road  
Eagan, Minnesota 55121

**TOLL FREE**

**Fax: 877.243.6930 Phone: 855.457.1200**

**CONFIDENTIALITY NOTICE:** This communication is intended only for the use of the individual entity to which it is addressed and may contain information that is privileged or confidential. If the reader of this message is not the intended recipient, you are hereby notified that any dissemination, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please notify the sender immediately by telephone at 866.202.3474 and return the original message to Prime Therapeutics via U.S. Mail. Thank you for your cooperation.